Zug, Switzerland, 14 October 2026 – Adalvo is pleased to announce the signing of a partnership agreement with Olpha for the commercialisation of semaglutide across Latvia, Lithuania and Estonia. The agreement was formalised during CPHI Milan 2026 and represents another important step in Adalvo's strategy to expand its presence in the rapidly growing GLP-1 receptor agonist market.
Through this collaboration, Adalvo and Olpha will combine their respective strengths to support the successful introduction and commercialisation of semaglutide in the Baltic region. The partnership brings together Adalvo's expertise in developing and delivering differentiated pharmaceutical solutions with Olpha's established commercial infrastructure, extensive market knowledge and strong presence across the Baltic healthcare landscape.
Semaglutide has emerged as one of the most significant therapeutic innovations in the management of cardiometabolic diseases, driving substantial transformation across the GLP-1 market. As demand for advanced treatment options continues to grow, the agreement positions both companies to capitalise on expanding market opportunities while supporting broader access to high-value therapies across the region.
"At Adalvo, we are committed to building strong partnerships that accelerate access to innovative treatment options across key markets. Olpha's established position in the Baltics makes them an ideal partner, and we look forward to working together to maximise the value of this collaboration and unlock the commercial potential of semaglutide across the region."
"By combining our regional expertise and commercial infrastructure with Adalvo's development capabilities, we aim to support broader access to treatment options and deliver lasting value for patients and healthcare professionals in Latvia, Lithuania and Estonia."
This partnership further strengthens Adalvo's growing GLP-1 platform and aligns with the strategic ambitions of its dedicated GLP-1 Business Unit. By combining Adalvo's international development expertise with Olpha's regional commercial excellence, the collaboration creates a strong foundation for long-term value creation, expands the reach of differentiated pharmaceutical solutions across the Baltic States, and reinforces both companies' positions within one of the pharmaceutical industry's fastest growing and most strategically important therapeutic segments.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.